about
Synthesis of 1,2,3-triazoles from xylosyl and 5-thioxylosyl azides: evaluation of the xylose scaffold for the design of potential glycogen phosphorylase inhibitors.Efficient atropodiastereoselective access to 5,5'-bis-1,2,3-triazoles: studies on 1-glucosylated 5-halogeno 1,2,3-triazoles and their 5-substituted derivatives as glycogen phosphorylase inhibitors.C-Glycopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential.3-Glucosylated 5-amino-1,2,4-oxadiazoles: synthesis and evaluation as glycogen phosphorylase inhibitors.Synthesis of 4-amidomethyl-1-glucosyl-1,2,3-triazoles and evaluation as glycogen phosphorylase inhibitors.Synthesis of dodecavalent fullerene-based glycoclusters and evaluation of their binding properties towards a bacterial lectin.Multivalent Glycomimetics with Affinity and Selectivity toward Fucose-Binding Receptors from Emerging Pathogens.Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines.An oxime-based glycocluster microarray.Tailor-made Janus lectin with dual avidity assembles glycoconjugate multilayers and crosslinks protocellsThe study of multivalent carbohydrate–protein interactions by bio-layer interferometryIdentification of Nanomolar Lectin Ligands by a Glycodendrimer MicroarrayGlucose-derived spiro-isoxazolines are anti-hyperglycemic agents against type 2 diabetes through glycogen phosphorylase inhibitionSelective high-resolution DNP-enhanced NMR of biomolecular binding sitesSynthesis of azido-functionalized carbohydrates for the design of glycoconjugatesSynthesis of 5-halogenated 1,2,3-triazoles under stoichiometric Cu(I)-mediated azide-alkyne cycloaddition (CuAAC or 'Click Chemistry')Multivalent glycoligands with lectin/enzyme dual specificity: self-deliverable glycosidase regulatorsMultifunctional Glycoconjugates for Recruiting Natural Antibodies against Cancer CellsHeteroglycoclusters With Dual Nanomolar Affinities for the Lectins LecA and LecB From Pseudomonas aeruginosaGlucose-based spiro-oxathiazoles as in vivo anti-hyperglycemic agents through glycogen phosphorylase inhibition
P50
Q30577251-25852B7C-F5F2-47E4-855C-DFEFF24C9EEDQ31154875-4B9559D3-88DE-4DAA-84C7-72B2E7E2E997Q39102713-0997EC58-F701-4D6C-9A5E-3182DF8AA807Q40259429-1BA364B5-C5ED-4758-ACDE-88607CED384EQ41701446-C115677A-C3A8-4820-9EDD-0978544FC006Q43487987-F9B1D296-CA51-4970-85B0-4934C46D5D6BQ47294427-A0273DDC-C083-4538-8557-D3DBCB76F436Q48169265-9F362407-E870-4FAC-BD49-8EDA07E279F3Q48766623-CBA930A0-DAC7-4192-98F7-FB711308E5D2Q57242691-11F008ED-A19A-4F8D-BD24-B473CEEFA04AQ58381305-BB4C8F39-0B97-4387-9ECE-53DD9F31282BQ58580959-17F525D9-7736-422C-BEDA-2F3CC1759D5FQ60657422-F7B28174-2DEB-4CD8-A90E-7DA131D65F40Q62421035-BC7CAD7E-D4EC-4F3A-8F52-F306520E5D2EQ82369775-E9222C45-3570-4849-9E36-4167BE1A3A1FQ85353871-5274495F-966F-4AA9-9CF5-3B5C42765050Q90606265-F5E675F4-06F6-4166-93BE-8B2385793682Q90712238-BC4AD539-C8C0-4EDE-BC2D-C6FF38D6053AQ90840286-FA42EAE6-D8BB-4A97-8442-8F49906745BBQ92545075-903401E9-5D6B-49C0-9BF5-D85327C3599B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David Goyard
@ast
David Goyard
@en
David Goyard
@es
David Goyard
@nl
type
label
David Goyard
@ast
David Goyard
@en
David Goyard
@es
David Goyard
@nl
prefLabel
David Goyard
@ast
David Goyard
@en
David Goyard
@es
David Goyard
@nl
P106
P1153
35198161000
P21
P31
P496
0000-0002-6410-0866